As mentioned previously, for several years now the golden standard for anti-angiogenic therapy in the treatment of advanced CRC has been the monoclonal antibody bevacizumab that targets the VEGF–VEGFR pathway activated in tumor-associated neo-vasculature by sequestering all isoforms of VEGF-A, the most potent pro-angiogenic growth factor compared to other VEGFs [63]. The gene discussed is VEGFA; the disease is colorectal carcinoma.